title: Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.
authors.affiliation: Retina Consultants of Houston, 6560 Fannin Street, Suite 750, Houston, TX 77030, USA. jcmmd@houstonretina.com
authors.forename: James C
authors.initials: JC
authors.lastname: Major
authors.forename: Seenu M
authors.initials: SM
authors.lastname: Hariprasad
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D057915:Drug Substitution; D006801:Humans; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab